Role of Vaspin in Pathophysiology of Pre-eclampsia

NCT06437535 | Not Yet Recruiting

• 1 other identifier: vaspin and pre-eclampsia
• Study Type: observational
• Target: 75
• Locations: 0 countries
• Sites: N/A

Brief Summary

• To investigate the possible role of vaspin and apoptosis in pre-eclamptic obese women .
• To compare the serum as well as placental level of vaspin in normotensive and severe pre-eclamptic obese women.
• To compare the serum as well as placental level of vaspin in normotensive normal body weight and severe pre-eclamptic obese women women .
• To compare placental apoptosis marker Bcl2 in normotensive and severe pre-eclamptic obese women .
• To compare placental apoptosis marker Bcl2 in normotensive normal body weight and severe pre-eclamptic obese women .
• Correlation between vaspin and apoptosis in pre-eclamptic obese women .
• Correlation between vaspin level and apoptosis marker with patient demographic data(Age -parity).

Conditions

Pre-Eclampsia

Outcome Measures

Primary Outcomes (3)

• vaspin level in serum and placenta

  \- measure level of vaspin in serum as well as its level in placenta in patients with pre-eclampsia and women with normal pregnancy

  one year

• level of bcl2 expression in placenta

  measure level of gene expression of apoptotic marker bcl2 by PCR in placenta in patients with preeclampsia and women with normal pregnancy

  one year

• vaspin and bcl2

  correlation between level of vaspin and bcl2 gene expression in patients of preeclamsia and women with normal pregnancy

  one year

Secondary Outcomes (1)

• vapin level and bcl2 level and patient demographic data

  one year

Study Arms (3)

Group 1

will include 25 women with normal weight and normal blood pressure .

Group2

:will include 25 obsese women with normal blood pressure.

Group 3

: will include 25 obese women with confirmed diagnosis of severe preeclampsia .

Eligibility Criteria

• Age: 18 Years - 35 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Pregnant women who will come for termination of pregnancy

You may qualify if:

• Pregnant women who will come to hospital for termination of pregnancy .
• Confirmed diagnosis of preeclampsia for study groups.
• Control group will include Normotensive pregnant women.
• Age group 18-35 years.
• gestional age at termination of pregnancy : group 1\&2 : from 38 to 40 weeks group 3:terminatin of pregnancy regardless of gestional age

You may not qualify if:

• Pregnant women who do not consent to participate.
• Diabeteic patients .
• History of pre-gestional hypertension.
• History of chronic renal disease.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (4)

• Bergman L, Torres-Vergara P, Penny J, Wikstrom J, Nelander M, Leon J, Tolcher M, Roberts JM, Wikstrom AK, Escudero C. Investigating Maternal Brain Alterations in Preeclampsia: the Need for a Multidisciplinary Effort. Curr Hypertens Rep. 2019 Aug 2;21(9):72. doi: 10.1007/s11906-019-0977-0.

  PMID: 31375930 BACKGROUND

• Fondjo LA, Sarpong D, Owiredu WKBA, Opoku S, Adu-Bonsaffoh K, Teviu E. Effect of magnesium sulfate treatment on mediators of endothelial dysfunction and electrolytes in mild and severe preeclampsia: A case-control study. Health Sci Rep. 2023 Apr 26;6(5):e1232. doi: 10.1002/hsr2.1232. eCollection 2023 May.

  PMID: 37123551 BACKGROUND

• Kurowska P, Mlyczynska E, Dawid M, Jurek M, Klimczyk D, Dupont J, Rak A. Review: Vaspin (SERPINA12) Expression and Function in Endocrine Cells. Cells. 2021 Jul 6;10(7):1710. doi: 10.3390/cells10071710.

  PMID: 34359881 BACKGROUND

• Kurowska P, Mlyczynska E, Dawid M, Opydo-Chanek M, Dupont J, Rak A. In Vitro Effects of Vaspin on Porcine Granulosa Cell Proliferation, Cell Cycle Progression, and Apoptosis by Activation of GRP78 Receptor and Several Kinase Signaling Pathways Including MAP3/1, AKT, and STAT3. Int J Mol Sci. 2019 Nov 19;20(22):5816. doi: 10.3390/ijms20225816.

  PMID: 31752432 BACKGROUND

MeSH Terms

Conditions

Pre-Eclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Central Study Contacts

Aya ali ibrahim sayed, master

CONTACT

+20 010096908832; ayaa.alii2468@gmail.com

Mahmoud Raafat Abdel-fadeil, professor

CONTACT

+20 01001644429; mrafadeil@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: principal investigator

Study Record Dates

• First Submitted: May 20, 2024
• First Posted: May 31, 2024
• Study Start: June 1, 2024
• Primary Completion: June 1, 2025
• Study Completion: August 1, 2025
• Last Updated: May 31, 2024

Record last verified: 2024-05